Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.

NCT06614322 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT06614322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06614322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.
Lead sponsor
University of Rochester
Phase
Phase 2
Overall status
Recruiting
Start date
February 2, 2026
Completion date
June 1, 2028
Enrollment
190 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced peripheral neuropathy (cipn), diabetic peripheral neuropathic pain (dpn), idiopathic peripheral neuropathy, painful peripheral neuropathy